SCHEMBL17752371

SCHEMBL17752371

COc1cc(-c2cccc(F)c2)c(F)cc1OBO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 1/20 0.46
▸ PDGFRA P16234 1/20 0.46
▸ FPR2 P25090 1/20 0.46
▸ FYN P06241 5/20 0.44
▸ KIT P10721 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ AHR P35869 1/20 0.40
▸ RELA Q04206 2/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ TUBB4A P04350 2/20 0.38
▸ TUBB P07437 2/20 0.38
▸ TUBA3C P0DPH7 2/20 0.38
▸ TUBA1B P68363 2/20 0.38
▸ TUBA4A P68366 2/20 0.38
▸ TUBB4B P68371 2/20 0.38
▸ TUBB3 Q13509 2/20 0.38
▸ TUBB2A Q13885 2/20 0.38
▸ TUBB8 Q3ZCM7 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15031948 0.86 PDGFRB (0.44) PDGFRBPDGFRAFYNKIT
SCHEMBL17752357 0.86 PDGFRB (0.44) PDGFRBPDGFRAFYNKIT
SCHEMBL17752376 0.86 FPR2 (0.44) FPR2FYN
SCHEMBL16303551 0.85 FPR2 (0.36) PDGFRBPDGFRAFPR2FYNKIT
SCHEMBL17752364 0.81 PDGFRB (0.52) PDGFRBPDGFRAFYNKITKDM4E
SCHEMBL16296759 0.78 FYN (0.47) PDGFRBPDGFRAFPR2FYNKIT
SCHEMBL17752374 0.78 MAPK10 (0.43) PDGFRBPDGFRAFYNKITPDE4B
SCHEMBL16311833 0.77 PDGFRB (0.47) PDGFRBPDGFRAFPR2FYNKIT
SCHEMBL16290837 0.77 PDGFRB (0.43) PDGFRBPDGFRAFPR2FYNKIT
SCHEMBL19890354 0.77 FYN (0.48) PDGFRBPDGFRAFPR2FYNKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 — — US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors SCN7A, SCN1A, SCN5A PDGFRB 3669/4885PDGFRA 2584/4885FPR2 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback